Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG –ACRIN 8143) A UROLOGIST’S PERSPECTIVE

Mohamad E. Allaf, MD, Associate Professor of Urology, Oncology, & BME MEA Endowed Director, Minimally Invasive Surgery
Johns Hopkins Medicine presents Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG ACRIN 8143) A UROLOGISTS PERSPECTIVE at the 2016 annual International Kidney Cancer Symposium.